Initial phase 2 trial of a nicotinic agonist in schizophrenia.
Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR.
Am J Psychiatry. 2008 Aug;165(8):1040-7. Epub 2008 Apr 1.PMID: 18381905 [PubMed - indexed for MEDLINE]Related articlesFree article